LDH 634 U/L in Testicular Cancer Evaluation and Management

1. Risk Stratification for Germ‑Cell Tumors

An LDH of 634 U/L (≈1.5–2 × upper‑limit of normal) classifies a patient with non‑seminomatous germ‑cell tumor (NSGCT) into the intermediate‑prognosis group, which is associated with a 5‑year progression‑free survival of 78 % and a 5‑year overall survival of 89 % according to the European Association of Urology (EAU) guidelines. 1
The same LDH level satisfies the intermediate‑prognosis LDH criterion (1.5–10 × ULN) when the primary tumor is testicular or retroperitoneal and there are no non‑pulmonary visceral metastases, as defined by the EAU. 1
For pure seminoma, LDH alone should not be used for staging or risk stratification, and treatment decisions must not be based solely on an elevated LDH. This is a Class I recommendation of the NCCN guidelines. [2][3]
In seminoma, concurrent elevations of β‑hCG and LDH do not alter management in the absence of radiographic disease, per NCCN guidance. [2][3]

Alpha‑fetoprotein (AFP) > 1 000 ng/mL indicates a good‑prognosis NSGCT, whereas AFP between 1 000–10 000 ng/mL denotes intermediate prognosis (EAU). 1
β‑hCG > 5 000 IU/L is a marker of intermediate‑prognosis NSGCT (EAU). 1
Repeat LDH measurement is recommended to confirm the elevation and to assess trend before treatment initiation (NCCN). [2][3]
Hemolysis work‑up: obtain a complete blood count with peripheral smear (NCCN). 3
Assess haptoglobin, indirect bilirubin, and reticulocyte count to evaluate hemolysis (NCCN). 2
Perform a direct antiglobulin (Coombs) test when immune‑mediated hemolysis is suspected (NCCN). 2

Testicular ultrasound should be performed when a scrotal mass or asymmetry is present (NCCN). 3
Contrast‑enhanced CT of the chest, abdomen, and pelvis is required within 4 weeks before any definitive therapy for suspected testicular cancer (NCCN). [2][3]
Brain MRI is indicated for patients with neurologic symptoms or markedly elevated tumor markers (EAU). 1

Do not initiate therapy based solely on an elevated LDH; treatment must be guided by imaging and clinical stage (NCCN). [2][3]
Obtain appropriate imaging (testicular ultrasound, CT) to identify any evaluable disease before deciding on therapy (NCCN). [2][3]
In stage IS (rising tumor markers without radiographic disease), repeat markers and imaging before commencing treatment (NCCN). [2][3]

AFP < 20 ng/mL does not reliably exclude germ‑cell tumor; management should not rely on minimally elevated AFP alone (NCCN). [2][3]
β‑hCG < 20 IU/L may be a false‑positive result due to hypogonadism or cannabis use; confirmatory testing is advised (NCCN). [2][3]
LDH elevation alone should never dictate treatment for pure seminoma without corroborating radiographic evidence (NCCN). [2][3]